Novartis says pelacarsen lowered the blood marker it was designed to lower. Its large heart-disease trial nevertheless did not demonstrate the clinical benefit it was designed to test. Those findings can coexist: changing a risk marker and preventing serious events are different results.

The distinction matters again because a follow-up paper published on November 7 revisits the same trial. Its published abstract does not establish a reduction in cardiovascular events in the additional analyses it describes. It is not a new trial reversing the original outcome.

Two Questions Inside One Trial

Pelacarsen is an investigational drug designed to reduce production of lipoprotein(a), usually shortened to Lp(a), a cholesterol-carrying particle associated with cardiovascular risk. Lowering its level can show that the treatment is reaching its biological target. The harder question is whether people receiving it fare better.

The randomized, placebo-controlled Phase 3 Lp(a)HORIZON trial enrolled 8,323 people with elevated Lp(a) and established cardiovascular disease. Both groups also received standard care. This was not a test of prevention in otherwise healthy people.

The registered primary outcome was the time until a participant’s first event in a defined combination: cardiovascular death, a nonfatal heart attack, a nonfatal stroke, or urgent treatment to restore blood flow through the heart’s arteries requiring hospitalization. Combining these events gave the trial a specified clinical test; it did not turn every component into a separately demonstrated result.

Change in Lp(a) at one year appears separately in the registry as a secondary outcome. The protocol therefore gives readers a useful distinction before any headline percentage: one measure asks what happened to the blood marker; the other asks what happened to patients, compared with placebo.

On September 4, Novartis reported that pelacarsen lowered Lp(a) but missed the primary cardiovascular-event endpoint. That is the sponsor’s account of the result. The registry confirms what the trial set out to test, not the reported treatment effect.

What the November Follow-Up Adds

The November 7 abstract in NEJM Evidence describes further analyses, including events during treatment and first plus recurrent events. It reports no association with a reduction in the combined cardiovascular outcome across the analyses examined.

These are additional views of the same study, not an independent replication. An analysis focused on time receiving treatment also asks a different question from the original randomized comparison. It cannot simply replace the trial’s primary test because it seems closer to how a drug should work. Our explanation of retatrutide’s two weight-loss estimates shows why the precise question behind a treatment estimate matters.

The follow-up claim here rests on the published abstract; the full methods and results were not available for this assessment. It therefore does not support a detailed judgment about subgroup benefits, safety, or the biological reason pelacarsen missed its endpoint.

A Better Measurement Is Not Automatically a Better Outcome

This does not make blood markers useless. The FDA’s explanation of biomarkers and surrogate endpoints distinguishes measurements that track a biological response from measures validated to predict a clinical benefit in a particular setting. The connection must be established, not assumed whenever a number improves.

Nor does a missed endpoint prove an effect of exactly zero. The result concerns this treatment, this comparison and this population. It does not establish that Lp(a) is irrelevant, that every drug targeting it must fail, or that each event in the combined endpoint was individually unaffected.

For pelacarsen, the decisive evidence was never going to be the blood test alone. The trial needed to show that adding the drug to standard care reduced its specified clinical events versus placebo. A lower Lp(a) level answers whether the target moved. The reported trial result does not establish that moving it delivered the clinical benefit the trial was designed to test.